Selective uptake of boronophenylalanine by glioma stem/progenitor cells.
The success of boron neutron capture therapy (BNCT) depends on the amount of boron in cells and the tumor/blood and tumor/(normal tissue) boron concentration ratios. For the first time, measurements of boron uptake in both stem/progenitor and differentiated glioma cells were performed along with measurements of boron biodistribution in suitable animal models. In glioma stem/progenitor cells, the selective accumulation of boronophenylalanine (BPA) was lower, and retention of boron after BPA removal was longer than in differentiated glioma cells in vitro. However, boron biodistribution was not statistically significantly different in mice with xenografts.
Neurosurgery and Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Ting
T
Sun
Youxin
Y
Zhou
Xueshun
X
Xie
Guilin
G
Chen
Bin
B
Li
Yongxin
Y
Wei
Jinming
J
Chen
Qiang
Q
Huang
Ziwei
Z
Du
D000818:Animals; D001880:Boranes / Q000493:pharmacokinetics*; D001932:Brain Neoplasms / Q000378:metabolism*; D045744:Cell Line, Tumor; D005910:Glioma / Q000378:metabolism*; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D014411:Neoplastic Stem Cells / Q000378:metabolism*; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D014018:Tissue Distribution
D001880:Boranes; C447034:boronophenylalaninol; D010649:Phenylalanine